← ANALYST RATINGS · TIPRANKS
Arcus Biosciences (RCUS): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy3 Hold0 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $39.75, the highest $50.00, the lowest $23.00. The average is +79.7% from the last price of $22.12.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.00 → $22.50−2.2% | Hold | +1.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.00 → $22.50−2.2% | Hold | +1.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.00 → $22.50−2.2% | Hold | +1.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.50 → $23.00−2.1% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $22.50 → $22.00−2.2% | Hold | −0.5% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Unknown Analyst | William Blair | $410 → $50.00−87.8% | Buy | +126.0% | Initiated | 15.10.26on TipRanks Oct 17 00:06 | +1.0%next day −2.0% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.50 → $21.50−8.5% | Hold | −2.8% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | $41.00 | Buy | +85.4% | Initiated | 14.10.26on TipRanks 05:16 | +1.2%next day +1.0% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $42.00 | Buy | +89.9% | Reiterated | 13.10.26on TipRanks Oct 14 09:45 | −7.5%next day +1.2% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $29.00 | Hold | +31.1% | Reiterated | 05.10.26on TipRanks 07:25 | +0.6%next day −2.4% · 5 days −2.0% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $46.00 | Buy | +108.0% | Reiterated | 03.10.26on TipRanks Oct 5 03:25 | +0.6%next day −2.4% · 5 days −2.0% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $43.00 | Buy | +94.4% | Reiterated | 30.09.26on TipRanks 09:15 | +0.9%next day −2.5% · 5 days −7.0% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $45.00 | Buy | +103.4% | Reiterated | 25.09.26on TipRanks 11:35 | −0.9%next day +0.9% · 5 days −1.9% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Initiated | 16.09.26on TipRanks 06:20 | +1.8%next day +2.5% · 5 days +5.0% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $45.00 | Buy | +103.4% | Reiterated | 09.09.26on TipRanks Sep 10 06:10 | −1.5%next day −7.6% · 5 days −12.4% | ↗ |
| Supawat Thongthip★★★★★★★★★★#6413 · hits 70% · avg +6.4% | Truist Financial | $35.00 → $40.00+14.3% | Buy | +80.8% | Reiterated | 08.09.26on TipRanks 07:08 | −1.5%next day −1.5% · 5 days −15.2% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $22.00 → $23.00+4.5% | Hold | +4.0% | Assigned | 10.08.26on TipRanks 08:21 | +0.4%next day +0.4% · 5 days +3.0% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $23.00 → $26.00+13.0% | Hold | +17.5% | Assigned | 06.08.26on TipRanks 06:10 | +2.4%next day +0.4% · 5 days +0.7% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $47.00 | Buy | +112.5% | Reiterated | 05.08.26on TipRanks Aug 6 11:07 | −3.6%next day +2.4% · 5 days +4.2% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $49.00 → $47.00−4.1% | Buy | +112.5% | Reiterated | 20.04.26on TipRanks 14:55 | −6.0%next day +8.5% · 5 days +8.8% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | — | Buy | — | Reiterated | 02.03.26on TipRanks Mar 3 04:15 | +17.5%next day −5.4% · 5 days −0.9% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $14.00 | Buy | −36.7% | Reiterated | 28.10.25on TipRanks Oct 29 03:30 | +6.6%next day +2.0% · 5 days +1.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Arcus Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.60 at a price of $25.83 (+49.4%); now: $39.75 at $22.12 (+79.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 5 | 6 | 10 | 14 | 14 |
| Buy | 7 | 7 | 7 | 6 | 6 | 4 |
| Hold | 2 | 2 | 1 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.88 (from $-1.00 to $-0.77). Last quarter: $-0.72.
Sales
Next quarter’s sales estimate — $9M (from $0M to $21M). Last quarter: $41M.
Best top-analyst consensus in the sector · Healthcare
About Arcus Biosciences
- CEO: Terry J. Rosen
- Employees: 601
- 3928 Point Eden Way, Hayward, CA, 94545, US
- arcusbio.com
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗